Biotech firm picks up 'milestone' contract deal

A life sciences firm has hailed its progress after securing a “milestone” contract extension. 

Aptamer Group is working with a top five global pharma company.

Bosses say the deal will see the York-based operator’s Optimer-branded alternative antibody molecules added to ELISA assays used to help detect substances in biological samples.

They add Aptamer has retained ownership of the binders’ intellectual property, “positioning the company to potentially establish commercialisation licenses in the future”.

Dr Arron Tolley, chief executive, added: “We are delighted to have successfully completed the initial binder development phase for this top five pharma partner and to now extend our collaboration into assay conversion. 

“This milestone not only validates the performance of our Optimer platform but also highlights its potential for broader applications in diagnostics and therapeutics.”

The deal comes after Aptamer Group said latest annual results left it primed for growth after a “pivotal” year of royalty and licensing deals.

Figures for the year to June 30 showed unaudited revenues had increased by more than 40 per cent to £1.20 million, with the firm’s progress boosted by an agreement with biotech firm Neuro-Bio on sales of diagnostics targeting Alzheimer’s disease.

Want your business, product or service to be seen regionally and nationally? Bdaily helps you get your story in front of the right audience, every day. Find out how Bdaily can help →

Join more than 55,000 subscribers by signing up to our daily bulletin each morning here.